mabtas 100mg
                     Mabtas 100mg - Anticancer drugs | view uses, 
side effects and price | MHP
MILLION HEALTH 
PHARMACEUTICALS
DESCRIPTION
 Mabtas 100mg is a anticancer medicine which 
prevents the growth and spread of cancer cells in the 
body. 
 Mabtas 100mg injection also indicated for the 
treatment of Non- Hodgkins lymphoma or chronic 
lymphocytic and with combination with another 
anticancer drugs like methotrexate is used for 
rheumatoid arthritis symptoms in adult treatment. 
 Mabtas 100mg with steroid regimen combination is 
given for the treatment of some rare disorders which 
cause blood vessels and other tissues inflammation in 
the body.
INDICATION
 Mabtas 100mg injection and hyaluronidase human 
injection are given alone or combination with another 
drugs to treat certain types of non-Hodgkin's lymphoma 
and chronic lymphocytic leukemia (cancer start in WBC). 
 Mabtas 100mg injection is also used with methotrexate 
(Otrexup, Rasuvo, Xatmep, others) for the treatment 
rheumatoid arthritis symptoms in adults that have been 
already treated with a some type of regimen known as 
tumor necrosis factor (TNF) inhibitor. Mabtas 100mg is a 
type in a classification of drugs called monoclonal 
antibodies.
Click icon to add picture
NON HODGKINS LYMPHOMA
PHARMACODYNAMIC
 new type of "targeted" cancer treatment and an integral part of 
the body's immune system. Naturally the body build antibodies 
in along with to an antigen which has entered the body and 
attach to the antigen for destruction by the immune system. An 
essential cells only aimed by monoclonal antibiotics, they may 
leads to less toxicity to healthy cell and it is usually treatment 
recommended only for cancers in which antigens (and the 
respective antibodies) have been already identified. Mabtas 
works by linking to the CD20 antigen on normal and malignant 
B-cells. Hence the body's essential immune security are 
initiated to attack and kill the marked B-cells. Stem cells 
i.eyoung cells in the bone marrow which will grow into the 
various cell types and do not have the CD20 antigen. After 
treatment,CD20 antigen allows healthy B-cells to multiply
Brand : Mabtas
Ingredients : 
Rituximab 
Strength : 100mg 
Manufactured : 
Intas 
pharmaceuticals
Package : 
injection
PRODUCT DETAILS
PHARMACOKINETICS
 ABSORPTION
Not available
DISTRIBUTION
volume of distribution is 3.1 L
METABOLISM
Mabtas 100mg injection metabolized by human 
antimurine antibody production.
EXCRETION
not available The half life of NHL is 22 days and for RA is 
18.0 days, GPA and microscopic polyangitis is 23 days
DOSAGE MANAGEMENT
 Mabtas 100mg is recommended to administer only through 
intravenous infusion not by IV push or bolus.
 ADMINISTRATION
Take an Mabtas 100 mg injection amount and diluted to 
final concentration of 1 mg/ml upto 4 mg/ml as infusion 
(containing either 0.9% Nacl or 5% dextrose in water). 
Invert gently the bag and mix the solution. Dispose unused 
drug left in vial. 
 OVERDOSAGE: If the patients had high dose of Mabtas
 100mg then seek immediately to the emergency 
department or poison control help line. Please consult the 
doctor for further clarification.
PRECAUTIONS
 Allgeric condition against Mabtas 100mg or any 
other medication informs your doctorWhile using 
Mabtas 100mg injection do not take any 
vaccination or immunization without taking advice 
from doctors. Avoid use of Mabtas 100mg if you are 
pregnant. It will harm the baby unborn, while using 
 Mabtas 100mg use correct birth control to prevent 
pregnancy and for at least 2 weeks after your 
treatment ends. 
 Mabtas 100mg injection may affect the ability to 
have children in women.
SIDE EFFECTS
   COMMON EFFECTS
 fever and chills (flu lik symptoms)
LESS COMMON SIDE EFFECTS
 Weakness; nausea; headache; cough; 
dyspnae; pharyngitis
DRUG INTERACTION
 Mabtas 100mg drug interaction has 
limited data is available at present. 
Combination with fludarabine or 
cyclophosphamide has no effects in 
pharmacokinetics in CLL patients. 
Combination with methotrexate had no 
effects in pharmacokinetics.
CONTRAINDICATIONS
 Hypersensitivity or murine proteins. 
Active severe infectons in rheumatoid 
arthritis Uncontrolled cardiac disease.
PREGNANCY
 CategoryC : animal studies 
reproduction shown an adverse effect 
on the fetus. The drug has no sufficient 
and well controlled studies in humans, 
using in pregnant women benefits by 
warrant use of the drug.
LACTATION
 Mabtas 100mg injection excreted into 
human milk is unknown. Due to the 
drug belongs to large protein molecule, 
no information is available. Women 
should not breast feed during Mabtas
 100mg treatment and 12 months 
following last dose.
STORAGE
 Store at 2°C – 3°C
Use the drug before expiry date
Protected from direct sunlight
Do not freeze or shake.
Keep away from the childerns
Discard the unused drug by asking the 
advice from doctor or pharmacist.
MISSED DOSE
 Store at 2°C – 3°C
Use the drug before expiry date
Protected from direct sunlight
Do not freeze or shake.
Keep away from the childerns
Discard the unused drug by asking the 
advice from doctor or pharmacist.
CONTACT US
 EMAIL ID :
    
[email protected]
m
 PHONE NO :
   +91-9940472902
 WEBSITE URL :       https
://millionpharma.com/mabtas-100mg.p
hp